Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma

doi:10.3748/wjg.v22.i33.7440

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 33

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11168)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

686

WORD

293

HTML

7315

Figures (1-1)

314

Tables (1-2)

245

Sum=8853

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1023

Download

1292

Sum=2315

Sep 7, 2016 (publication date) through Nov 3, 2024

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Sep 7, 2016; 22(33): 7440-7452
Published online Sep 7, 2016. doi: 10.3748/wjg.v22.i33.7440

Open in New Tab Full Size Figure Download Figure

Figure 1 Various inflammation-associated signaling pathways activated in Kras mutant pancreatic cancer cells, as novel treatment targets. CXCL5: C-X-C motif chemokine ligand 5; ERK: Extracellular signal-regulated kinase; IL: Interleukin; JAK: Janus kinase; NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; STAT: Signal transducer and activator of transcription; TNF: Tumor necrosis factor; TNF-R: TNF-receptor.

Citation: Kimbara S, Kondo S. Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma. World J Gastroenterol 2016; 22(33): 7440-7452
URL: https://www.wjgnet.com/1007-9327/full/v22/i33/7440.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i33.7440